Publications

Divergent trajectories of antiviral memory after SARS-CoV-2 infection

Tomic A. et al, (2022), Nature Communications, 13

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.

Donovan-Banfield I. et al, (2022), Nat Commun, 13

An introduction to the Marburg virus vaccine consortium, MARVAC.

Cross RW. et al, (2022), PLoS pathogens, 18

Avatar Mice Underscore the Role of the T Cell-Dendritic Cell Crosstalk in Ebola Virus Disease and Reveal Mechanisms of Protection in Survivors.

Rottstegge M. et al, (2022), Journal of virology

Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.

Wing PAC. et al, (2022), PLoS pathogens, 18

A prototype lateral flow assay for detection of orthopoxviruses.

Ulaeto DO. et al, (2022), The Lancet. Infectious diseases, 22, 1279 - 1280

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

McNaughton AL. et al, (2022), JCI Insight, 7

Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.

Harvala H. et al, (2022), Transfusion, 62, 1347 - 1354

Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages.

Prince T. et al, (2022), mSphere

SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients

Shankar S. et al, (2022), Journal of the American Society of Nephrology, 33, 883 - 887

Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction.

Guimond SE. et al, (2022), ACS central science, 8, 527 - 545

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Ogbe A. et al, (2022), JCI Insight, 7

Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing

Salam AP. et al, (2022), PLOS Neglected Tropical Diseases, 16, e0010289 - e0010289

Multisystem screening reveals SARS-CoV-2 in neurons of the myenteric plexus and in megakaryocytes.

Gray-Rodriguez S. et al, (2022), The Journal of pathology

Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers

Dong X. et al, (2022), GigaScience, 11

Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.

Mellors J. et al, (2022), Frontiers in immunology, 13

Development of anti-Crimean-Congo hemorrhagic fever virus Gc and NP-specific ELISA for detection of antibodies in domestic animal sera.

Belij-Rammerstorfer S. et al, (2022), Frontiers in veterinary science, 9

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.

Longet S. et al, (2022), Frontiers in immunology, 13

The characterization of multiple novel paramyxoviruses highlights the diverse nature of the subfamily Orthoparamyxovirinae.

Vanmechelen B. et al, (2022), Virus evolution, 8

Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses.

Gartlan C. et al, (2022), Frontiers in immunology, 13

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Tan TK. et al, (2021), Nature Communications, 12

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

Lambe T. et al, (2021), Communications Biology, 4

Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013–16 West Africa epidemic

Tipton TRW. et al, (2021), Nature Communications, 12

Quantification of type i interferon inhibition by viral proteins: Ebola virus as a case study

Locke M. et al, (2021), Viruses, 13

Severity of heterosubtypic influenza virus infection in ferrets is reduced by live attenuated influenza vaccine

Marriott AC. et al, (2021), npj Vaccines, 6

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

Skelly DT. et al, (2021), Nature Communications, 12

Dose-Dependent Response to Infection with Ebola Virus in the Ferret Model and Evidence of Viral Evolution in the Eye.

Watson RJ. et al, (2021), Journal of virology, 95

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Payne RP. et al, (2021), Cell, 184, 5699 - 5714.e11

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Ogbe A. et al, (2021)

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.

Huo J. et al, (2021), Nature communications, 12

Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.

Hargreaves A. et al, (2021), Pathogens (Basel, Switzerland), 10

Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks.

Keita AK. et al, (2021), Nature, 597, 539 - 543

Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques

Bewley KR. et al, (2021), Science Advances, 7

Amplicon and Metagenomic Analysis of Middle East Respiratory Syndrome (MERS) Coronavirus and the Microbiome in Patients with Severe MERS.

Aljabr W. et al, (2021), mSphere, 6

INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies.

van Haren FMP. et al, (2021), British journal of clinical pharmacology, 87, 3075 - 3091

One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.

Gooch KE. et al, (2021), Vaccine, 39, 4885 - 4894

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu C. et al, (2021), Cell, 184, 4220 - 4236.e13

Metagenomic identification of a new sarbecovirus from horseshoe bats in Europe.

Crook JM. et al, (2021), Scientific reports, 11

Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season

Xu Y. et al, (2021), Eurosurveillance, 26

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays.

Bewley KR. et al, (2021), Nature protocols, 16, 3114 - 3140

Diagnosis of SARS-CoV-2 Infection with LamPORE, a High-Throughput Platform Combining Loop-Mediated Isothermal Amplification and Nanopore Sequencing

Peto L. et al, (2021), Journal of Clinical Microbiology, 59

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

McNaughton AL. et al, (2021)

Antibody evasion by the P.1 strain of SARS-CoV-2

Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9

T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study

Angyal A. et al, (2021), SSRN Electronic Journal

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6

Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study

Thom R. et al, (2021), The Lancet Infectious Diseases, 21, 507 - 516

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Dejnirattisai W. et al, (2021), Cell, 184, 2183 - 2200.e22

Cookies on this website

Publications